Sixty years of amphotericin B: an overview of the main antifungal agent used to treat invasive fungal infections
FB Cavassin, JL Baú-Carneiro, RR Vilas-Boas… - Infectious Diseases and …, 2021 - Springer
Introduced in the late 1950s, polyenes represent the oldest family of antifungal drugs. The
discovery of amphotericin B and its therapeutic uses is considered one of the most important …
discovery of amphotericin B and its therapeutic uses is considered one of the most important …
Drug resistance and treatment failure in leishmaniasis: A 21st century challenge
A Ponte-Sucre, F Gamarro, JC Dujardin… - PLoS neglected …, 2017 - journals.plos.org
Reevaluation of treatment guidelines for Old and New World leishmaniasis is urgently
needed on a global basis because treatment failure is an increasing problem. Drug …
needed on a global basis because treatment failure is an increasing problem. Drug …
Drug resistance in leishmaniasis
Leishmaniasis is a complex disease, with visceral and cutaneous manifestations, and is
caused by over 15 different species of the protozoan parasite genus Leishmania. There are …
caused by over 15 different species of the protozoan parasite genus Leishmania. There are …
Leishmaniasis: current status of available drugs and new potential drug targets
The control of Leishmania infection relies primarily on chemotherapy till date. Resistance to
pentavalent antimonials, which have been the recommended drugs to treat cutaneous and …
pentavalent antimonials, which have been the recommended drugs to treat cutaneous and …
Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani
The clinical value of amphotericin B, the mainstay therapy for visceral leishmaniasis in
sodium antimony gluconate-nonresponsive zones of Bihar, India, is now threatened by the …
sodium antimony gluconate-nonresponsive zones of Bihar, India, is now threatened by the …
Amphotericin B: A drug of choice for Visceral Leishmaniasis
Visceral leishmaniasis or Kala-azar is a vector-borne disease caused by an intracellular
parasite of the genus leishmania. In India, Amphotericin B (AmB) is a first-line medication for …
parasite of the genus leishmania. In India, Amphotericin B (AmB) is a first-line medication for …
Drug resistance in leishmaniasis
J Chakravarty, S Sundar - Journal of global infectious diseases, 2010 - journals.lww.com
The treatment options of leishmaniasis are limited and far from satisfactory. For more than 60
years, treatment of leishmaniasis has centered around pentavalent antimonials (Sb v) …
years, treatment of leishmaniasis has centered around pentavalent antimonials (Sb v) …
Fruitful decade for antileishmanial compounds from 2002 to late 2011
Leishmaniasis, usually caused by the genus Leishmania, has not received the attention it
deserves and in recent times has developed into a major health problem worldwide. 1, 2 …
deserves and in recent times has developed into a major health problem worldwide. 1, 2 …
Mucosal leishmaniasis: current scenario and prospects for treatment
Leishmaniasis causes significant morbidity and mortality and thus constitutes a serious
public health problem. Even though it has long been endemic in developing countries, in …
public health problem. Even though it has long been endemic in developing countries, in …
In vitro and in vivo interactions between miltefosine and other antileishmanial drugs
K Seifert, SL Croft - Antimicrobial agents and chemotherapy, 2006 - Am Soc Microbiol
The interaction of miltefosine with amphotericin B, sodium stibogluconate, paromomycin,
and sitamaquine was assessed in vitro and additionally for the first three combinations in …
and sitamaquine was assessed in vitro and additionally for the first three combinations in …